# Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin SELECT found composite cardiovascular events at 6.5% vs 8.0% (HR 0.80). Stroke measured alone rests on one underpowered trial and a cohort where it did not move. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-prevent-stroke Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin The headline cardiovascular results are composites that pool stroke with heart attack and cardiovascular death. Measured on its own, stroke has one small trial its own authors discount. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Composite outcomes, then stroke on its own · 1.0 · MACE, SELECT · MACE, 11 trials · stroke recurrence · ischemic stroke · A composite moving is not stroke moving. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - The large trials report MACE — a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke. The composite moves. - SELECT found 6.5% against 8.0% in 17,604 people (HR 0.80, 95% CI 0.72 to 0.90). A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87. - Stroke measured on its own is far thinner. One dedicated trial found recurrence at 7.9% against 13.8%, and its authors call it underpowered. - A large matched cohort found ischemic stroke unchanged at HR 0.91 (95% CI 0.64 to 1.28) while heart attack fell. The honest answer depends on a distinction most summaries skip. The headline cardiovascular results are composites, and a composite moving is not the same as stroke moving. This site reads effect estimates the same way in [sixteen percent lower, six hundredths of a point](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy). ## What the big trials actually counted SELECT randomized 17,604 people with cardiovascular disease and a BMI of 27 or more, without diabetes, to semaglutide 2.4 mg or placebo [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-1). A primary event occurred in 6.5% of the semaglutide group against 8.0% on placebo, a hazard ratio of 0.80 with an interval from 0.72 to 0.90. That primary endpoint is death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke, counted as time to first event. Stroke is one of three components, and the trial was not designed to size stroke alone. A meta-analysis of 11 trials covering 85,373 participants reports the same shape [\[2\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-2). In the 67,769 participants with type 2 diabetes, GLP-1 drugs reduced MACE by 13% (HR 0.87, 95% CI 0.81 to 0.93). All-cause death fell 12% (HR 0.88, 0.83 to 0.93). The kidney half of that analysis sits alongside [the growing dialysis evidence base](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). A composite can move on one component Three outcomes are pooled into MACE, and a drug that strongly reduces one of them will move the composite even if the others barely shift. This site has seen exactly that: a matched cohort of 52,971 adults found heart attack fell (HR 0.67) while ischemic stroke did not (HR 0.91, 95% CI 0.64 to 1.28, number needed to treat 2,500) — set out in [the cohort that tested its own bias](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes). Read the components, not the composite. ## The one trial built around stroke LAMP randomized 636 patients with type 2 diabetes who had a minor ischemic stroke or a high-risk transient ischemic attack, within 24 hours of symptom onset [\[3\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-3). One arm received liraglutide for 90 days on top of guideline care; the other received guideline care alone. Hazard ratio 0.56 (95% CI 0.34 to 0.91); odds ratio 1.95 (1.28 to 3.00). | Outcome at 90 days | Liraglutide + standard care | Standard care alone | | --- | --- | --- | | Stroke recurrence | 25 of 316 (7.9%) | 44 of 318 (13.8%) | | Excellent functional outcome | 87.3% | 77.8% | Hazard ratio 0.56 (95% CI 0.34 to 0.91); odds ratio 1.95 (1.28 to 3.00). LAMP, 27 hospitals in China Both outcomes favored liraglutide. The authors then state that, given the underpowered nature of the study, the findings should be interpreted with caution — a caveat this site usually has to supply itself. Underpowered means the trial enrolled fewer patients than needed to reliably detect the effect it tested. A positive result from such a trial is more likely to overstate the effect, and more likely to shrink on replication. Two further limits. The design was open-label with blinded endpoint assessment, so patients and treating doctors knew the assignment while outcome assessors did not. And participants were Chinese, which the authors note when framing their conclusion. ## Where that leaves the question Composite cardiovascular outcomes improve, consistently, across large trials and a large meta-analysis. Stroke measured on its own has one small dedicated trial that its own authors discount, and one large cohort in which it did not move. So the defensible statement is that these drugs reduce cardiovascular events overall, and that the stroke-specific contribution is not established. That is a narrower claim than most pages make, and it is the one the evidence supports. The distinction between preventing something and treating it is set out in [why preventing something is not treating it](https://thisglp.com/research/preventing-it-is-not-treating-it). Nothing here is a reason to start or stop a medication after a stroke. That decision involves blood pressure, anticoagulation, the cause of the stroke and much else, and it belongs to the clinicians managing it. ## Frequently asked Do GLP-1 drugs prevent stroke? They reduce composite cardiovascular events, which include stroke alongside heart attack and cardiovascular death. Stroke measured on its own is not established: one dedicated trial is underpowered by its authors' own account, and a large cohort found ischemic stroke unchanged. What did SELECT find? A primary event in 6.5% on semaglutide against 8.0% on placebo across 17,604 people, a hazard ratio of 0.80. That endpoint pools cardiovascular death, non-fatal heart attack and non-fatal stroke. What is MACE? A composite outcome — usually cardiovascular death, non-fatal myocardial infarction and non-fatal stroke counted together. A drug that strongly reduces one component moves the composite even if the others barely shift. Does liraglutide help after a minor stroke? In the LAMP trial, recurrence was 7.9% against 13.8% over 90 days. The authors describe the trial as underpowered and advise caution, and it was open-label with blinded endpoint assessment. ## Sources 1. \[1\] Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The New England Journal of Medicine. [PMID 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/) 2. \[2\] Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials The Lancet Diabetes & Endocrinology. [PMID 39608381](https://pubmed.ncbi.nlm.nih.gov/39608381/) 3. \[3\] Zhu H, Yang B, Lu L, Li Y, Sui R, Liu K (2026). Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial JAMA Internal Medicine. [PMID 41182740](https://pubmed.ncbi.nlm.nih.gov/41182740/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)